Russell D. Cohen to Humans
This is a "connection" page, showing publications Russell D. Cohen has written about Humans.
Connection Strength
1.107
-
Looking from the Past to the Future: How Janus Kinase Inhibitors Have Altered the Therapy of Ulcerative Colitis. Dig Dis Sci. 2023 06; 68(6):2248-2251.
Score: 0.030
-
Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis. Dig Dis Sci. 2022 Nov; 67(11):5010-5013.
Score: 0.029
-
Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. Dig Dis Sci. 2022 03; 67(3):805-809.
Score: 0.028
-
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
Score: 0.025
-
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis. 2020 Feb 10; 14(2):192-204.
Score: 0.024
-
Maneuvering Clinical Pathways for Crohn's Disease. Curr Gastroenterol Rep. 2019 Apr 23; 21(5):20.
Score: 0.023
-
Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
Score: 0.019
-
Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. Inflamm Bowel Dis. 2015 Jul; 21(7):1719-36.
Score: 0.018
-
Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015 Jun; 18(6):447-56.
Score: 0.017
-
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
Score: 0.017
-
Dietary fiber intake and Crohn's disease. Gastroenterology. 2014 Apr; 146(4):1133.
Score: 0.016
-
Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012 Sep 24; 12:132.
Score: 0.015
-
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
Score: 0.013
-
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. Drug Des Devel Ther. 2011 Feb 27; 5:111-6.
Score: 0.013
-
The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):103-9.
Score: 0.012
-
Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010 Apr; 31(7):693-707.
Score: 0.012
-
How should we treat severe acute steroid-refractory ulcerative colitis? Inflamm Bowel Dis. 2009 Jan; 15(1):150-1.
Score: 0.011
-
Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis. 2008 Dec; 14(12):1707-14.
Score: 0.011
-
Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008 Dec; 10(6):585-90.
Score: 0.011
-
What is the optimal maintenance treatment for ulcerative colitis? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S236-7.
Score: 0.011
-
Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008 Jun; 14(6):738-43.
Score: 0.011
-
Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007 Nov 01; 26(9):1179-86.
Score: 0.010
-
Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007 Nov; 62(11):1013-4.
Score: 0.010
-
Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007 Oct; 1(1):101-12.
Score: 0.010
-
Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):867-82.
Score: 0.010
-
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006 Oct; 12(10):979-94.
Score: 0.010
-
Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Aug 01; 24(3):465-74.
Score: 0.009
-
MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006 May; 130(6):1923-4.
Score: 0.009
-
Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results? Gastroenterology. 2006 Feb; 130(2):607-8; discussion 608.
Score: 0.009
-
Postoperative management of ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005 Dec; 7(6):492-9.
Score: 0.009
-
Worms, germs and IBD: is it your mother's fault? Gastroenterology. 2005 Sep; 129(3):1127-8; discussion 1128-9.
Score: 0.009
-
Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005 Jan 06; 57(2):281-302.
Score: 0.009
-
Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep. 2004 Dec; 6(6):488-95.
Score: 0.008
-
Sperm, sex, and 6-MP: the perception on conception. Gastroenterology. 2004 Oct; 127(4):1263-4.
Score: 0.008
-
Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004 Jun; 33(2):235-50, viii.
Score: 0.008
-
Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004; 64(16):1767-77.
Score: 0.008
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
Score: 0.008
-
Infliximab at 5 years--tweaking the recipe for success? Gastroenterology. 2003 Dec; 125(6):1902-3.
Score: 0.008
-
Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 10 03; 29(10):1658-1661.
Score: 0.008
-
IBD indirect costs: the sleeping giant? Gastroenterology. 2003 Sep; 125(3):982-4.
Score: 0.008
-
Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 Jun; 29(6):1520-1529.
Score: 0.008
-
Infliximab in ulcerative colitis: is there a placebo (effect) in the house? Gastroenterology. 2003 Jun; 124(7):1990-1; discussion 1991.
Score: 0.008
-
IBD: the drugs work...but do the patients? Am J Gastroenterol. 2003 Apr; 98(4):722-3.
Score: 0.008
-
Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
Score: 0.008
-
The mesalamine wars heat up-enter balsalazide. Gastroenterology. 2003 Feb; 124(2):574-5.
Score: 0.007
-
Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2002 Dec; 4(6):497-505.
Score: 0.007
-
Methotrexate in IBD--move over 6-MP? Not so fast... Gastroenterology. 2002 Nov; 123(5):1737-9.
Score: 0.007
-
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
Score: 0.007
-
The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther. 2002 Sep; 16(9):1603-9.
Score: 0.007
-
Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1386-1394.
Score: 0.007
-
Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002 Aug; 35(2):151-6.
Score: 0.007
-
Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2023 03; 68(3):897-901.
Score: 0.007
-
Endoscopy of the small bowel in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002 Jul; 12(3):485-93.
Score: 0.007
-
Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology. 2002 Jun; 122(7):2082-4; discussion 2084.
Score: 0.007
-
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 07; 163(1):204-221.
Score: 0.007
-
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
Score: 0.007
-
Crohn's disease and Takayasu's arteritis. J Clin Gastroenterol. 2002 Apr; 34(4):454-6.
Score: 0.007
-
Cost utility of initial medical management for Crohn's disease perianal fistula. Gastroenterology. 2002 Apr; 122(4):1187-8; author reply 1188-90.
Score: 0.007
-
Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
Score: 0.007
-
Endoscopy in inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):119-32.
Score: 0.007
-
Infliximab as first-line therapy for severe Crohn's disease? Inflamm Bowel Dis. 2002 Jan; 8(1):58-9; discussion 63-5.
Score: 0.007
-
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Dig Dis. 2022; 40(5):553-564.
Score: 0.007
-
Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2001 Dec; 3(6):464-70.
Score: 0.007
-
Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
Score: 0.007
-
Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
Score: 0.007
-
Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
Score: 0.007
-
Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology. 2001 May; 120(6):1541-3.
Score: 0.007
-
Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis. 2001 May; 7 Suppl 1:S17-22.
Score: 0.007
-
The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
Score: 0.006
-
Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
Score: 0.006
-
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
Score: 0.006
-
Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44.
Score: 0.006
-
Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77.
Score: 0.006
-
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.
Score: 0.006
-
Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
Score: 0.006
-
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Aliment Pharmacol Ther. 2020 08; 52(3):559-560.
Score: 0.006
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.006
-
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
Score: 0.006
-
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76.
Score: 0.006
-
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
Score: 0.006
-
The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000 Feb; 95(2):524-30.
Score: 0.006
-
The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. Semin Gastrointest Dis. 2000 Jan; 11(1):10-7.
Score: 0.006
-
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
Score: 0.006
-
Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
Score: 0.006
-
Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
Score: 0.006
-
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
Score: 0.006
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.006
-
Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol. 2020 04; 18(4):987-988.e1.
Score: 0.006
-
Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
Score: 0.006
-
Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92.
Score: 0.006
-
Validation of health-related quality of life instruments. Hepatology. 1999 Jun; 29(6 Suppl):7S-8S.
Score: 0.006
-
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
Score: 0.006
-
Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
Score: 0.006
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.006
-
Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
Score: 0.006
-
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 Feb; 5(1):1-10.
Score: 0.006
-
Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-a4ß7 and anti-PD1 antibodies. J Immunother Cancer. 2019 01 06; 7(1):1.
Score: 0.006
-
A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
Score: 0.005
-
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688.
Score: 0.005
-
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
Score: 0.005
-
Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
Score: 0.005
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.005
-
Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
Score: 0.005
-
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
Score: 0.005
-
Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
Score: 0.005
-
The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
Score: 0.005
-
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501.
Score: 0.005
-
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
Score: 0.005
-
Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
Score: 0.005
-
Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):99-105.
Score: 0.005
-
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
Score: 0.005
-
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
Score: 0.005
-
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
Score: 0.005
-
Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
Score: 0.005
-
Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology. 1996 May; 110(5):1658-62.
Score: 0.005
-
Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
Score: 0.005
-
The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7.
Score: 0.005
-
Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol. 1995 Dec; 90(12):2090-2.
Score: 0.005
-
Ulcerative Colitis Care Pathway. Gastroenterology. 2015 Jul; 149(1):238-45.
Score: 0.004
-
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
Score: 0.004
-
Impact of internal health locus of control on health outcomes for older men and women: a longitudinal perspective. Gerontologist. 1994 Jun; 34(3):299-306.
Score: 0.004
-
Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23.
Score: 0.004
-
The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013 Dec; 19(13):2778-86.
Score: 0.004
-
Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
Score: 0.004
-
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
Score: 0.004
-
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
Score: 0.004
-
Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012 Nov-Dec; 18(9):701-12.
Score: 0.004
-
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22.
Score: 0.004
-
Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
Score: 0.003
-
Sex differentials in morbidity and mortality risks examined by age and cause in the same cohort. Am J Epidemiol. 1989 Sep; 130(3):601-10.
Score: 0.003
-
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
Score: 0.003
-
Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol. 2009 Aug; 43(7):613-6.
Score: 0.003
-
Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
Score: 0.002
-
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006 Oct; 12(10):972-8.
Score: 0.002
-
Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol. 2006 Sep; 40(8):669-77.
Score: 0.002
-
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex. 2006 Jul-Sep; 71(3):351-401.
Score: 0.002
-
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8.
Score: 0.002
-
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30.
Score: 0.002
-
Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin. 2006 May; 22(5):989-1000.
Score: 0.002
-
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):935-9.
Score: 0.002
-
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):940-87.
Score: 0.002
-
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005 Mar 15; 21(6):733-8.
Score: 0.002
-
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9.
Score: 0.002
-
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
Score: 0.002
-
Collagenous gastritis: an unusual association with profound weight loss. Arch Pathol Lab Med. 2004 Feb; 128(2):229-32.
Score: 0.002
-
First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6.
Score: 0.002
-
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33.
Score: 0.002
-
Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc. 1980 Mar; 55(3):146-55.
Score: 0.002
-
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7.
Score: 0.001
-
Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28.
Score: 0.001
-
An increasing prevalence of hearing impairment and associated risk factors over three decades of the Alameda County Study. Am J Public Health. 1997 Mar; 87(3):440-2.
Score: 0.001
-
Correlation of nuclear morphometry and DNA ploidy in rectal cancer. Dis Colon Rectum. 1991 Jun; 34(6):449-54.
Score: 0.001